Top

Published in:

01-02-2021 | Immunodeficiency | Letter to Editor

Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy

Authors: Jonathan London, David Boutboul, Karine Lacombe, France Pirenne, Beate Heym, Valérie Zeller, Antoine Baudet, Amani Ouedrani, Alice Bérezné

Published in: Journal of Clinical Immunology | Issue 2/2021

Excerpt

To the Editor, …

Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.05.06.20092999.

Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, et al. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211–213.e4.CrossRef

Fill L, Hadney L, Graven K, Persaud R, Hostoffer R. The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease 2019. Ann Allergy Asthma Immunol 2020;125(1):112–114.

Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2020;31:565–9.CrossRef

Bearden D, Collett M, Quan PL, Costa-Carvalho BT, Sullivan KE. Enteroviruses in X-linked agammaglobulinemia: update on epidemiology and therapy. J Allergy Clin Immunol Pract. 2016;4:1059–65.CrossRef

Jongco AM, Gough JD, Sarnataro K, Rosenthal DW, Moreau J, Ponda P, et al. X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii. Ann Allergy Asthma Immunol. 2014;112:74–75.e2.

Malphettes M, Gérard L, Galicier L, Boutboul D, Asli B, Szalat R, et al. Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;61:e13–9.CrossRef

Malphettes M, Gérard L, Carmagnat M, Mouillot G, Vince N, Boutboul D, et al. Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis Off Publ Infect Dis Soc Am. 2009;49:1329–38.CrossRef

Hueso T, Pouderoux C, Péré H, Beaumont A-L, Raillon L-A, Ader F, et al. Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease. Blood. 2020.

10.

Burbelo PD, Browne SK, Sampaio EP, Giaccone G, Zaman R, Kristosturyan E, et al. Anti-cytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia. Blood. 2010;116:4848–58.CrossRef

11.

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann H-H, Zhang Y, et al. Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585.CrossRef

12.

Browne SK, Zaman R, Sampaio EP, Jutivorakool K, Rosen LB, Ding L, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood. 2012;119:3933–9.CrossRef

Title: Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
Authors: Jonathan London
David Boutboul
Karine Lacombe
France Pirenne
Beate Heym
Valérie Zeller
Antoine Baudet
Amani Ouedrani
Alice Bérezné
Publication date: 01-02-2021
Publisher: Springer US
Keywords: Immunodeficiency
SARS-CoV-2
COVID-19
Published in: Journal of Clinical Immunology / Issue 2/2021
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-020-00904-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2021

Functional Asplenia and Specific Polysaccharide Antibody Deficiency in a Girl with SAVI

Primary Immunodeficiencies in India: Molecular Diagnosis and the Role of Next-Generation Sequencing

Targeted Proteomics Reveals Inflammatory Pathways that Classify Immune Dysregulation in Common Variable Immunodeficiency

Reduced Intensity Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Pediatric Inherited Immune Deficiencies and Bone Marrow Failure Syndromes

Safety and Tolerability of Subcutaneous IgPro20 at High Infusion Parameters in Patients with Primary Immunodeficiency: Findings from the Pump-Assisted Administration Cohorts of the HILO Study

Primary Cutaneous Aspergillosis in a Patient with CARD9 Deficiency and Aspergillus Susceptibility of Card9 Knockout Mice

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials